Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires $225,746.15 in Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri purchased 28,043 shares of Nuvectis Pharma stock in a transaction on Wednesday, June 18th. The shares were purchased at an average cost of $8.05 per share, with a total value of $225,746.15. Following the transaction, the insider now owns 2,976,203 shares in the company, valued at approximately $23,958,434.15. The trade was a 0.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Tuesday, June 17th, Marlio Charles Mosseri acquired 5,399 shares of Nuvectis Pharma stock. The shares were bought at an average price of $8.11 per share, for a total transaction of $43,785.89.
• On Monday, May 12th, Marlio Charles Mosseri acquired 21,167 shares of Nuvectis Pharma stock. The stock was bought at an average cost of $8.11 per share, with a total value of $171,664.37.
• On Thursday, May 8th, Marlio Charles Mosseri acquired 2,650 shares of Nuvectis Pharma stock. The stock was bought at an average cost of $8.65 per share, with a total value of $22,922.50.
• On Tuesday, May 6th, Marlio Charles Mosseri acquired 12,444 shares of Nuvectis Pharma stock. The stock was bought at an average cost of $8.59 per share, with a total value of $106,893.96.

Nuvectis Pharma Stock Performance

NVCT traded up $0.08 during trading hours on Friday, reaching $8.13. The company's stock had a trading volume of 93,851 shares, compared to its average volume of 129,786. Nuvectis Pharma, Inc. has a 52 week low of $4.44 and a 52 week high of $11.80. The company's 50-day moving average is $9.28 and its 200-day moving average is $7.68. The firm has a market cap of $169.84 million, a PE ratio of -7.19 and a beta of -0.16.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. Equities analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on NVCT shares. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective (up previously from $11.00) on shares of Nuvectis Pharma in a report on Wednesday, April 30th. Laidlaw started coverage on Nuvectis Pharma in a report on Monday, March 17th. They issued a "buy" rating and a $19.00 price objective for the company. Finally, Maxim Group began coverage on Nuvectis Pharma in a report on Wednesday, April 2nd. They issued a "buy" rating and a $17.00 price objective for the company.

Institutional Investors Weigh In On Nuvectis Pharma

Large investors have recently added to or reduced their stakes in the business. Baldwin Wealth Partners LLC MA increased its position in Nuvectis Pharma by 0.7% during the 1st quarter. Baldwin Wealth Partners LLC MA now owns 358,461 shares of the company's stock worth $3,502,000 after buying an additional 2,500 shares during the period. Iridian Asset Management LLC CT bought a new position in Nuvectis Pharma during the 1st quarter worth $2,481,000. Marshall Wace LLP increased its position in Nuvectis Pharma by 191.0% during the 4th quarter. Marshall Wace LLP now owns 124,571 shares of the company's stock worth $674,000 after buying an additional 81,757 shares during the period. Goldman Sachs Group Inc. bought a new position in Nuvectis Pharma during the 1st quarter worth $446,000. Finally, Jane Street Group LLC bought a new position in Nuvectis Pharma during the 1st quarter worth $413,000. Institutional investors own 96.77% of the company's stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.